pasireotide (signifor) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (ssts). Pasireotide binds and activates the hsst receptors resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$172.0262 - $223.1163
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cyclo((4r)-4-(2-aminoethylcarbamoyloxy)-l-prolyl-l-phenylglycyl-d-tryptophyl-l-lysyl-4-o-benzyl-l-tyrosyl-l- phenylalanyl-) | cyclo((4r)-4-(2-aminoethylcarbamoyloxy)-l-prolyl-l-phenylglycyl-d-tryptophyl-l-lysyl-4-o-benzyl-l-tyrosyl-l-phenylalanyl-) | pasireotida | pasireotide | pasiréotide | pasireotide diaspartate | pasireotide disapartate | pasireotide embonate | pasireotide pamoate | pasireotidum | signifor | som230 | som 230 | som-230

Organizations (50)

Research & Development (50)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (52)

Approved Indications (2)


 

Acromegaly

Pituitary ACTH Hypersecretion (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (52)


 

Acromegaly (Phase 4)

ACTH Syndrome, Ectopic (Phase 2)

Adenoma (Phase 2)

Adenoma, Islet Cell (Phase 2)

Alcoholism (Phase 1)

Angiodysplasia (Phase 2)

Bariatric Surgery (Phase 2)

Breast Carcinoma In Situ (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoid Tumor (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Congenital Hyperinsulinism (Phase 2)

Cushing Syndrome (Phase 2)

Drugs, Investigational (Phase 2)

Dumping Syndrome (Phase 4)

Enterostomy (Phase 2)

General Surgery (Phase 4)

Gigantism (Phase 2)

Headache (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 2)

Hyperglycemia (Phase 2)

Hyperinsulinism (Phase 2)

Hyperplasia (Phase 1)

Hypoglycemia (Phase 4)

Insulinoma (Phase 2)

Intestinal Neoplasms (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Cirrhosis (Phase 1)

Liver Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 4)

Meningioma (Phase 2)

Multiple Myeloma (Phase 2)

Nelson Syndrome (Phase 2)

Neoplasms (Phase 4)

Neuroendocrine Tumors (Phase 4)

Obesity (Phase 4)

Pancreatic Fistula (Phase 4)

Pancreatic Neoplasms (Phase 4)

Peritoneal Neoplasms (Phase 2)

Pituitary ACTH Hypersecretion (Phase 4)

Pituitary Neoplasms (Phase 4)

Polycystic Kidney, Autosomal Dominant (Phase 2)

Postoperative Complications (Phase 2)

Prolactinoma (Phase 2/Phase 3)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Thymoma (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial Organizations: 50

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue